S1 Ep31: Behind the Science of Molecular Targeting of Biologics
Sep 23, 2021•17 min•Season 1Ep. 31
Episode description
This episode highlights findings from an investigative study exploring the molecular targeting of biologics for psoriasis, as well as discusses the interleukin(IL)-17 class of biologics, how this class compares to other classes such as IL-23 and TNFα, and how bimekizumab sets itself apart from other biologics in the pipeline for psoriasis.
For the best experience, listen in Metacast app for iOS or Android
